Moderna and CARsgen team up on CAR-T cell therapy and mRNA cancer vaccine combo

CARs­gen will test its Claudin18.2 CAR T-cell can­di­date, dubbed CT041, in com­bi­na­tion with Mod­er­na’s in­ves­ti­ga­tion­al mR­NA can­cer vac­cine in a col­lab­o­ra­tion be­tween the two com­pa­nies.

As part of the col­lab­o­ra­tion, the two can­di­dates will be in­ves­ti­gat­ed in pre­clin­i­cal and Phase I stud­ies. Mod­er­na’s can­cer vac­cine is de­signed around the Claudin18.2 pro­tein.

CARs­gen is al­ready in­ves­ti­gat­ing CT041 in gas­tric, pan­cre­at­ic and oth­er di­ges­tive sys­tem can­cers in sev­er­al tri­als in Chi­na and North Amer­i­ca. Ac­cord­ing to CARS­gen, CT041 is the “most ad­vanced” sol­id tu­mor CAR-T in de­vel­op­ment, as it is in sev­er­al Phase I and II tri­als. It was grant­ed an or­phan drug des­ig­na­tion from the FDA in 2020 and re­gen­er­a­tive med­i­cine ad­vanced ther­a­py des­ig­na­tion in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.